Saturday 17 October 2026
Export ELOX’s income statement to Excel — free account
Senesco Technologies Inc.
ELOX Healthcare Biotechnology
Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million. In the quarter to June 2026, EPS grew 87.7% and free cash flow fell 144.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
13.03
0.67
−4.89%
Follow ELOX
| Jun '17 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | — | 0.00 | — |
P/S ratio |
— | — | — | — | — | — | — | — | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | — | — | (382.85) | — |
P/FCF ratio |
— | — | — | — | — | — | — | — | 0.00 | — |
P/Operating CF |
— | — | — | — | — | — | — | — | (8.85) | — |
P/B ratio |
— | — | — | — | — | — | — | — | 0.00 | — |
Price to Tangible BV |
— | — | — | — | — | — | — | — | 0.00 | — |
EV/Sales |
— | — | — | — | — | — | — | — | 0.00 | — |
EV/EBITDA |
— | — | — | — | — | — | — | — | 0.00 | — |
EV/Operating CF |
— | — | — | — | — | — | — | — | (5.55) | — |
EV/FCF |
— | — | — | — | — | — | — | — | (5.81) | — |
Quick Ratio |
0.01 | 7.06 | 6.23 | 4.77 | 2.51 | 4.28 | 0.84 | 0.06 | 0.10 | 0.28 |
Current Ratio |
0.10 | 7.16 | 6.45 | 4.89 | 2.63 | 4.37 | 0.87 | 0.07 | 0.11 | 0.31 |
Net Debt/EBITDA |
0.01 | 1.23 | 1.03 | 0.83 | 0.41 | 0.47 | 0.21 | (0.15) | (3.49) | 0.61 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 25.17% | 43.87% | 26.58% | 59.35% | 223.77% | 218.95% | 18.98% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.41 | 1.14 | 0.54 | (1.18) | (0.17) | (0.27) | (0.08) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.71 | 0.00 |
Operating CF/Net income |
0.31 | 0.67 | 0.66 | 0.77 | 0.81 | 0.52 | 0.88 | 0.84 | 1.50 | 1.06 |
Capex/Depreciation |
1.08 | (0.34) | (1.06) | (0.05) | 0.00 | (0.06) | (0.05) | 0.29 | 0.06 | 0.00 |
Interest Coverage |
(17.32) | — | — | — | — | — | — | — | — | — |
| (228.24%) | (212.48%) | (146.83%) | (128.59%) | (148.90%) | (409.19%) | (615.23%) | 102.55% | 13.39% | 33.08% | |
| (211.94%) | (154.22%) | (124.99%) | (92.78%) | (80.95%) | (186.35%) | (108.86%) | (149.37%) | (134.09%) | (145.40%) | |
ROIC |
(342.55%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
254.01% | (110.57%) | (110.29%) | (110.35%) | (213.60%) | (197.76%) | 1,291.26% | 80.77% | 12.92% | 50.35% |
Average Days of Receivables |
— | — | — | — | — | — | — | — | 156.01 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 56.25% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 82.56% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8.51% | 0.00% |
Graham Net Nets |
— | — | — | — | — | — | — | — | (0.16) | — |
Graham Number |
— | — | — | — | — | — | — | — | 0.00 | — |
Earnings Yield |
— | — | — | — | — | — | — | — | (151.20%) | — |
Free Cash Flow Yield |
— | — | — | — | — | — | — | — | (15.86%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.61 | 0.00 |
Operating CF per Share |
(36.46) | (1,410.18) | (425.60) | (455.39) | (308.84) | (220.13) | (161.73) | (61.36) | (13.80) | (5.64) |
Capex per Share |
0.90 | (20.97) | (3.11) | (0.44) | 0.00 | (0.56) | (0.34) | 1.32 | 0.11 | 0.00 |
Free Cash Flow per Share |
(35.56) | (1,431.15) | (428.71) | (455.83) | (308.84) | (220.69) | (162.07) | (60.04) | (13.69) | (5.64) |
Cash per Share |
0.63 | 2,137.26 | 660.12 | 651.09 | 271.10 | 267.72 | 98.87 | 5.79 | 0.34 | 4.27 |
Shareholders Equity per Share |
16.50 | 1,890.35 | 582.24 | 418.65 | 112.17 | 140.78 | (54.14) | (96.70) | (71.22) | (10.61) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
16.50 | 1,890.35 | 582.24 | 418.65 | 112.17 | 140.78 | (54.14) | (96.70) | (71.22) | (10.61) |
Free Cash Flow |
(1.88) | (16.17) | (31.60) | (39.43) | (28.17) | (35.09) | (31.91) | (14.03) | (4.68) | (6.33) |
Working Capital |
(2.49) | 21.08 | 42.53 | 45.90 | 16.06 | 33.53 | (2.96) | (21.15) | (24.33) | (11.91) |
Capital Expenditures |
0.05 | (0.24) | (0.23) | (0.04) | — | (0.09) | (0.07) | 0.31 | 0.04 | 0.00 |
Net Current Asset Value |
(4.69) | 21.08 | 42.53 | 34.98 | 9.65 | 20.73 | (11.65) | (22.76) | (24.33) | (11.91) |
EV/EBIT |
— | — | — | — | — | — | — | — | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | — | — | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.86 | 2.54 | 0.87 | 3.95 | 8.64 | 6.39 | 7.31 | 30.51 | 0.00 | 0.00 |
Cash ROIC |
(207.61%) | (35.53%) | (34.51%) | (36.72%) | (60.48%) | (45.60%) | (149.50%) | 80.58% | 26.42% | 103.43% |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | — | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
0.14 | 0.86 | 1.14 | 1.31 | 1.18 | 0.93 | 2.20 | 4.36 | 5.52 | 4.03 |
Average Assets |
2.92 | 15.31 | 37.75 | 54.83 | 42.71 | 35.81 | 33.13 | 11.42 | 2.34 | 4.12 |
Average Common Equity |
2.71 | 11.12 | 32.14 | 39.56 | 23.22 | 16.31 | 5.86 | (16.63) | (23.47) | (18.12) |
Columns are period end dates